DiaMedica Therapeutics Files Q3 2024 10-Q

TL;DR

DiaMedica's Q3 2024 10-Q is in. Check financials.

AI Summary

DiaMedica Therapeutics Inc. filed its Q3 2024 10-Q report on November 13, 2024, covering the period ending September 30, 2024. The company, previously known as DiaMedica Inc., is focused on pharmaceutical preparations. Key financial details and operational updates for the third quarter are detailed within this filing.

Why It Matters

This filing provides investors and stakeholders with the latest financial performance and operational status of DiaMedica Therapeutics Inc. for the third quarter of 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, DiaMedica Therapeutics Inc. faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.

Key Players & Entities

• DiaMedica Therapeutics Inc. (company) — Filer of the 10-Q report
• 20240930 (date) — End of the reporting period
• 20241113 (date) — Filing date of the report
• DiaMedica Inc. (company) — Former name of the company

FAQ

Filing Documents

• dmtp20240930_10q.htm (10-Q) — 836KB
• ex_743381.htm (EX-3.1) — 2KB
• ex_743362.htm (EX-31.1) — 12KB
• ex_743363.htm (EX-31.2) — 12KB
• ex_743364.htm (EX-32.1) — 4KB
• ex_743365.htm (EX-32.2) — 5KB
• image1.jpg (GRAPHIC) — 58KB
• image01.jpg (GRAPHIC) — 157KB
• image2.jpg (GRAPHIC) — 184KB
• image3.jpg (GRAPHIC) — 64KB
• 0001437749-24-034925.txt ( ) — 4889KB
• dmac-20240930.xsd (EX-101.SCH) — 39KB
• dmac-20240930_def.xml (EX-101.DEF) — 265KB
• dmac-20240930_lab.xml (EX-101.LAB) — 223KB
• dmac-20240930_pre.xml (EX-101.PRE) — 290KB
• dmac-20240930_cal.xml (EX-101.CAL) — 31KB
• dmtp20240930_10q_htm.xml (XML) — 598KB

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 SIGNATURE PAGE 24 This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, that are subject to the safe harbor created by those sections. For more information, see " Cautionary Note Regarding Forward-Looking Statements. " As used in this report, references to " DiaMedica, " the " Company, " " we, " " our " or " us, " unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica ' s condensed consolidated financial statements. References in this report to " common shares " mean our voting common shares, no par value per share. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the and symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies ' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS DiaMedica Therapeutics Inc. Condensed Consolidated Balance Sheets (In thousands, except share amounts) September 30, 2024 December 31, 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 4,134 $ 4,543 Marketable securities 46,063 48,352 Amounts receivable 290 369 Prepaid expenses and other assets 280 411 Total current assets 50,767 53,675 Non-current assets: Deposits 1,308 — Operating lease right-of-use asset, net 298 354 Property and equipment, net 151 131 Total non-current assets 1,757 485 Total assets $ 52,524 $ 54,160 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,171 $ 926 Accrued liabilities 3,024 1,777 Operating lease obligation 88 80 Finance lease obligation 14 3 Total current liabilities 4,297 2,786 Non-current liabilities: Operating lease obligation 249 316 Finance lease obligation 14 1 Total non-current liabilities 263 317 Shareholders' equity: Common shares, no par value; unlimited authorized; 42,766,497 and 37,958,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively — — Paid-in capital 179,985 166,609 Accumulated other comprehensive income 81 6 Accumulated deficit ( 132,102 ) ( 115,558 ) Total shareholders' equity 47,964 51,057 Total liabilities and shareholders' equity $ 52,524 $ 54,160 See accompanying notes to the condensed consolidated financial statements. 3 DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 4,983 $ 3,272 $ 12,587 $ 9,433 General and administrative 1,900 1,885 5,675 5,986 Operating loss ( 6,883 )

View Full Filing

View this 10-Q filing on SEC EDGAR